DK2041308T3 - Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren - Google Patents

Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren

Info

Publication number
DK2041308T3
DK2041308T3 DK07786793.5T DK07786793T DK2041308T3 DK 2041308 T3 DK2041308 T3 DK 2041308T3 DK 07786793 T DK07786793 T DK 07786793T DK 2041308 T3 DK2041308 T3 DK 2041308T3
Authority
DK
Denmark
Prior art keywords
detection
mage
probes
marker
diagnosis
Prior art date
Application number
DK07786793.5T
Other languages
Danish (da)
English (en)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK2041308T3 publication Critical patent/DK2041308T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK07786793.5T 2006-06-21 2007-06-21 Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren DK2041308T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
DK2041308T3 true DK2041308T3 (da) 2012-10-08

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07786793.5T DK2041308T3 (da) 2006-06-21 2007-06-21 Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren

Country Status (27)

Country Link
US (1) US8936919B2 (cg-RX-API-DMAC7.html)
EP (1) EP2041308B1 (cg-RX-API-DMAC7.html)
JP (2) JP2009540812A (cg-RX-API-DMAC7.html)
KR (1) KR101455589B1 (cg-RX-API-DMAC7.html)
CN (1) CN101506383B (cg-RX-API-DMAC7.html)
AU (1) AU2007263019B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2656909A1 (cg-RX-API-DMAC7.html)
CO (1) CO6140072A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113290T1 (cg-RX-API-DMAC7.html)
DK (1) DK2041308T3 (cg-RX-API-DMAC7.html)
EA (1) EA016347B1 (cg-RX-API-DMAC7.html)
ES (1) ES2389513T3 (cg-RX-API-DMAC7.html)
GB (1) GB0612342D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20120761T1 (cg-RX-API-DMAC7.html)
IL (1) IL195975A (cg-RX-API-DMAC7.html)
MA (1) MA30565B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008016493A (cg-RX-API-DMAC7.html)
MY (1) MY147511A (cg-RX-API-DMAC7.html)
NO (1) NO20085290L (cg-RX-API-DMAC7.html)
NZ (1) NZ573809A (cg-RX-API-DMAC7.html)
PL (1) PL2041308T3 (cg-RX-API-DMAC7.html)
PT (1) PT2041308E (cg-RX-API-DMAC7.html)
SI (1) SI2041308T1 (cg-RX-API-DMAC7.html)
UA (1) UA95956C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007147876A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810695B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596545A (en) 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
ATE209690T1 (de) * 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
DE60234115D1 (de) * 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
ATE522620T1 (de) * 2002-11-14 2011-09-15 Wayne John Cancer Inst Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
IL195975A (en) 2012-08-30
PL2041308T3 (pl) 2012-11-30
US8936919B2 (en) 2015-01-20
GB0612342D0 (en) 2006-08-02
ES2389513T3 (es) 2012-10-26
HRP20120761T1 (hr) 2012-10-31
CA2656909A1 (en) 2007-12-27
CY1113290T1 (el) 2016-04-13
HK1127627A1 (en) 2009-10-02
WO2007147876A2 (en) 2007-12-27
JP2009540812A (ja) 2009-11-26
MX2008016493A (es) 2009-05-21
EA200802356A1 (ru) 2009-06-30
JP2013046630A (ja) 2013-03-07
SI2041308T1 (sl) 2012-10-30
EP2041308B1 (en) 2012-07-11
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
US20120040341A1 (en) 2012-02-16
NZ573809A (en) 2011-12-22
JP5705191B2 (ja) 2015-04-22
BRPI0713599A2 (pt) 2012-11-06
AU2007263019B2 (en) 2012-11-08
UA95956C2 (uk) 2011-09-26
WO2007147876A3 (en) 2008-05-15
CO6140072A2 (es) 2010-03-19
CN101506383A (zh) 2009-08-12
CN101506383B (zh) 2013-08-28
KR101455589B1 (ko) 2014-10-28
AU2007263019A1 (en) 2007-12-27
KR20090034900A (ko) 2009-04-08
IL195975A0 (en) 2009-09-01
NO20085290L (no) 2009-01-19
EA016347B1 (ru) 2012-04-30
MY147511A (en) 2012-12-31
EP2041308A2 (en) 2009-04-01
PT2041308E (pt) 2012-10-09

Similar Documents

Publication Publication Date Title
DK2371958T3 (da) HIDTIL UKENDTE siRNA OG FREMGANGSMÅDER TIL ANVENDELSE DERAF
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
BRPI0818801A2 (pt) Sistema de testes de diagnóstico.
BRPI0814320A2 (pt) Método para determinar automaticamente o estado de uso de um dispositivo médico eletrônico e/ou ativar dito dispositivo médico eletrônico, e, estetoscópio eletrônico.
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
EP2068698A4 (en) INCLUDED TEST UNIT FOR CHECKING BODY FLUIDS
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI1010798A2 (pt) fechamento, aparelho de retenção, e método de uso do mesmo
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
EP1896842A4 (en) Non-destructive testing of pipes
BRPI1013971A2 (pt) métodos e aparelho para medição de fluido multifásico.
DK2029220T3 (da) Medicinsk sonde
DK2157903T3 (da) Fremgangsmåde til iagttagelsesmåling
EP2150625A4 (en) METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC RESISTANT BACTERIA
BRPI1008534A2 (pt) aparelho e métodos para testar fluido de furo de poço
BRPI0814330A2 (pt) métodos e kits cirúrgicos
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
BRPI0910030A2 (pt) método de teste ultra-sônico e equipamento para o mesmo.
BR112012010208A2 (pt) método, sistema, e estojo de distribuição química
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
EP2281903A4 (en) CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE
NO20083908L (no) Fluidanalysesystem og metode for drift av et analysesystem
DE602007006745D1 (de) Sondenvorrichtung
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.